PH12022553118A1 - Treatment of conditions associated with thyroid hormone - Google Patents
Treatment of conditions associated with thyroid hormoneInfo
- Publication number
- PH12022553118A1 PH12022553118A1 PH1/2022/553118A PH12022553118A PH12022553118A1 PH 12022553118 A1 PH12022553118 A1 PH 12022553118A1 PH 12022553118 A PH12022553118 A PH 12022553118A PH 12022553118 A1 PH12022553118 A1 PH 12022553118A1
- Authority
- PH
- Philippines
- Prior art keywords
- conditions associated
- thyroid hormone
- treatment
- compositions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013960P | 2020-04-22 | 2020-04-22 | |
| US202063088523P | 2020-10-07 | 2020-10-07 | |
| US202163135118P | 2021-01-08 | 2021-01-08 | |
| PCT/US2021/028675 WO2021216896A1 (en) | 2020-04-22 | 2021-04-22 | Treatment of conditions associated with thyroid hormone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022553118A1 true PH12022553118A1 (en) | 2023-04-03 |
Family
ID=78270024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/553118A PH12022553118A1 (en) | 2020-04-22 | 2021-04-22 | Treatment of conditions associated with thyroid hormone |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230149410A1 (enExample) |
| EP (1) | EP4138809A4 (enExample) |
| JP (1) | JP2023522956A (enExample) |
| KR (1) | KR20230015906A (enExample) |
| CN (1) | CN115916177A (enExample) |
| AU (1) | AU2021260956A1 (enExample) |
| BR (1) | BR112022021420A2 (enExample) |
| CA (1) | CA3175608A1 (enExample) |
| IL (1) | IL297453A (enExample) |
| MX (1) | MX2022013140A (enExample) |
| PH (1) | PH12022553118A1 (enExample) |
| WO (1) | WO2021216896A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025522112A (ja) * | 2022-07-11 | 2025-07-10 | プリズム・エルエルシー | アラン・ハーンドン・ダドリー症候群を治療するための方法 |
| CA3261855A1 (en) * | 2022-07-11 | 2024-01-18 | PriZm, LLC | METHODS AND FORMULATIONS OF GENE THERAPY, AND OF COMBINATION OF GENE THERAPY WITH DITPA THERAPY, FOR ALLAN-HERNDON-DUDLEY SYNDROME |
| US20240350591A1 (en) * | 2023-04-12 | 2024-10-24 | Xygenyx Inc. | Composition and methods of treatment using synergistically-enhanced supplementation |
| CN121910745B (zh) * | 2026-03-23 | 2026-05-26 | 暨南大学 | N-乙酰神经氨酸在制备治疗甲基苯丙胺成瘾的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1243101A (en) * | 1999-10-28 | 2001-05-08 | Cary Pharmaceuticals Inc. | High dose folic acid for the treatment of hyperhomocysteinemia |
| IT1320776B1 (it) * | 2000-08-07 | 2003-12-10 | Giampiero Valletta | Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie |
| HRP20160406T1 (hr) * | 2009-07-10 | 2016-05-20 | Linzy O. Scott Iii | Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima |
| WO2012171065A1 (en) * | 2011-06-17 | 2012-12-20 | Esra Ogru | Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa). |
| US10640748B2 (en) * | 2014-12-24 | 2020-05-05 | Neuorphan Pty Ltd | Oligodendroglial cell culturing methods and in methods for treating neurodegenerative disorders by using thyroid hormones or analogues |
| US20160339086A1 (en) * | 2015-05-19 | 2016-11-24 | Suzy Cohen | Compositions and methods for treating thyroid disease |
-
2021
- 2021-04-22 EP EP21793379.5A patent/EP4138809A4/en active Pending
- 2021-04-22 CA CA3175608A patent/CA3175608A1/en active Pending
- 2021-04-22 US US17/996,865 patent/US20230149410A1/en active Pending
- 2021-04-22 PH PH1/2022/553118A patent/PH12022553118A1/en unknown
- 2021-04-22 AU AU2021260956A patent/AU2021260956A1/en not_active Abandoned
- 2021-04-22 CN CN202180030618.0A patent/CN115916177A/zh active Pending
- 2021-04-22 JP JP2022564128A patent/JP2023522956A/ja active Pending
- 2021-04-22 MX MX2022013140A patent/MX2022013140A/es unknown
- 2021-04-22 IL IL297453A patent/IL297453A/en unknown
- 2021-04-22 BR BR112022021420A patent/BR112022021420A2/pt unknown
- 2021-04-22 KR KR1020227039930A patent/KR20230015906A/ko active Pending
- 2021-04-22 WO PCT/US2021/028675 patent/WO2021216896A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4138809A1 (en) | 2023-03-01 |
| MX2022013140A (es) | 2022-11-16 |
| EP4138809A4 (en) | 2024-05-01 |
| CA3175608A1 (en) | 2021-10-28 |
| CN115916177A (zh) | 2023-04-04 |
| US20230149410A1 (en) | 2023-05-18 |
| KR20230015906A (ko) | 2023-01-31 |
| AU2021260956A1 (en) | 2022-11-17 |
| IL297453A (en) | 2022-12-01 |
| WO2021216896A1 (en) | 2021-10-28 |
| BR112022021420A2 (pt) | 2022-12-27 |
| JP2023522956A (ja) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013140A (es) | Tratamiento de afecciones asociadas con la hormona tiroidea. | |
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| IL143313A0 (en) | Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases | |
| MX2022011550A (es) | Composiciones y métodos para inhibir la expresión de angptl3. | |
| PH12021552024A1 (en) | Treatment of kidney injury | |
| PH12021552763A1 (en) | Treatment and prevention of metabolic diseases | |
| WO2019246262A3 (en) | Methods of treating or inhibiting onset of huntington's disease | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2010003548A (es) | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. | |
| MY199903A (en) | Combination therapy with controlled-release cnp agonists | |
| FR2706767B1 (enExample) | ||
| MX2020009942A (es) | Compuestos y usos de los mismos. | |
| PH12021550176A1 (en) | Method for treating epilepsy | |
| WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
| IL96146A0 (en) | Method of treating anxietyrelated disorders using sertraline | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2020003042A (es) | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. | |
| MX2025001444A (es) | Anticuerpos monoclonales anti-trkb y metodos de uso | |
| WO2019103658A3 (ru) | Производные 1,4-бензодиазепин-2-она и их применение | |
| ZA202106809B (en) | Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| WO2020154571A8 (en) | Compounds and uses thereof | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. |